Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 August 2020Website:
http://www.nautilus.bioNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 15 Nov 2024 21:02:43 GMTDividend
Analysts recommendations
Institutional Ownership
NAUT Latest News
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder and Chief Executive Officer Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Operator Good day everyone, and thank you for standing by and welcome to Nautilus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) will be hosting its Q1 2024 Earnings Conference Call on April 30, 2024 at 8:30 AM ET. Presenting will be Sujal Patel, Co-Founder & CEO, Parag Mallick, Co-Founder & Chief Scientist, and Anna Mowry, CFO. Thank you for joining the call.
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Carrie Mendivil - IR Sujal Patel - Co-Founder & CEO Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - CFO Conference Call Participants Yuko Oku - Morgan Stanley Daniel Brennan - Cowen Ivy Kozlowski - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Carrie Mendivil - Investor Relations Sujal Patel - Co-Founder, Chief Executive Officer, President, Secretary & Director Parag Mallick - Co-Founder, Chief Scientist & Director Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Dave Delahunt - Goldman Sachs Dan Brennan - Cowen Operator Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.
SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter before market open on Wednesday, August 2, 2023.
SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:
What type of business is Nautilus Biotechnology?
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
What sector is Nautilus Biotechnology in?
Nautilus Biotechnology is in the Healthcare sector
What industry is Nautilus Biotechnology in?
Nautilus Biotechnology is in the Biotechnology industry
What country is Nautilus Biotechnology from?
Nautilus Biotechnology is headquartered in United States
When did Nautilus Biotechnology go public?
Nautilus Biotechnology initial public offering (IPO) was on 07 August 2020
What is Nautilus Biotechnology website?
https://www.nautilus.bio
Is Nautilus Biotechnology in the S&P 500?
No, Nautilus Biotechnology is not included in the S&P 500 index
Is Nautilus Biotechnology in the NASDAQ 100?
No, Nautilus Biotechnology is not included in the NASDAQ 100 index
Is Nautilus Biotechnology in the Dow Jones?
No, Nautilus Biotechnology is not included in the Dow Jones index
When was Nautilus Biotechnology the previous earnings report?
No data
When does Nautilus Biotechnology earnings report?
The next expected earnings date for Nautilus Biotechnology is 28 February 2025